Umb Bank, N.A. Vertex Pharmaceuticals Inc Transaction History

Umb Bank, N.A.

$6.3 Billion
Q3 2024

A detailed history of Umb Bank, N.A. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Umb Bank, N.A. holds 5,194 shares of VRTX stock, worth $2.12 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

5,194

Previous 5,226 0.61%

Holding current value

$2.12 Million

Previous $2.45 Million 1.39%

% of portfolio

0.04%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$460.0 - $505.78 $14,720 - $16,184	-32 Reduced 0.61%	5,194 $2.42 Million
Q2 2024 Jul 29, 2024	SELL	$392.81 - $485.53 $458,016 - $566,127	-1,166 Reduced 18.24%	5,226 $2.45 Million
Q1 2024 Apr 26, 2024	SELL	$407.69 - $446.08 $12.3 Million - $13.4 Million	-30,103 Reduced 82.49%	6,392 $2.67 Million
Q4 2023 Jan 23, 2024	SELL	$343.0 - $410.68 $723,387 - $866,124	-2,109 Reduced 5.46%	36,495 $14.8 Million
Q3 2023 Oct 18, 2023	SELL	$338.18 - $362.46 $1.28 Million - $1.38 Million	-3,798 Reduced 8.96%	38,604 $13.4 Million
Q2 2023 Jul 25, 2023	BUY	$314.42 - $351.91 $94,326 - $105,573	300 Added 0.71%	42,402 $14.9 Million
Q1 2023 Apr 11, 2023	SELL	$283.23 - $323.1 $369,898 - $421,968	-1,306 Reduced 3.01%	42,102 $13.3 Million
Q4 2022 Jan 10, 2023	BUY	$285.76 - $321.48 $297,761 - $334,982	1,042 Added 2.46%	43,408 $12.5 Million
Q3 2022 Oct 13, 2022	BUY	$273.83 - $305.53 $5.85 Million - $6.53 Million	21,362 Added 101.7%	42,366 $12.3 Million
Q2 2022 Jul 20, 2022	BUY	$234.96 - $292.55 $4.89 Million - $6.09 Million	20,829 Added 11902.29%	21,004 $5.92 Million
Q1 2022 Apr 22, 2022	BUY	$221.42 - $260.97 $221 - $260	1 Added 0.57%	175 $46,000
Q4 2021 Feb 09, 2022	BUY	$177.01 - $223.45 $30,799 - $38,880	174 New	174 $38,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Umb Bank, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Umb Bank, N.A. with notifications on news.

Account